United States Securities and Exchange Commission · EDGAR Accession 0001610315-26-000002

Form C

Offering Statement — Regulation Crowdfunding
Issuer CIK 1610315
Raising via StartEngine Primary, LLC

Oxeia Biopharmaceuticals, Inc.

CorporationDEIncorporated 2014Boston, MAoxeiabiopharma.com
A

The Offering

as disclosed in this filing
Other (Series CF Preferred Stock)
$0.79
$20,000
$1,235,000
April 6, 2026
Expired 69 days ago
$0max $1,235,000

Target is 2% of the maximum. Over-subscriptions accepted.

B

Financial Condition

two fiscal years, as filed
Pre-revenueBurn decreasingDebt / assets 5322%2 employees
Line itemMost recent FYPrior FYΔ
Revenue00
Cost of goods sold00
Net income(1,219,002)(1,939,043)▲ burn
Total assets233,373211,440▲ 10%
Cash & equivalents25,4667,715▲ 230%
Accounts receivable00
Short-term debt8,520,2237,812,933▲ 9%
Long-term debt3,898,9473,628,497▲ 7%
Taxes paid00

Figures in USD as reported by the issuer. Securities offered in all 50 states.